ArticleEndocrine2025
Bone health and body composition in Indian girls with Turner syndrome: analysis based on therapeutic interventions.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTurner syndrome (TS) is associated with multiple factors contributing to compromised bone health. This study aims to evaluate bone health in Indian girls with TS based on the therapeutic interventions they have undergone. Additionally, it seeks to identify key determinants of bone health parameters in them.
methods70 karyotype-proven girls and young adults (4–25 years) with TS were included. Clinico-demographic data and laboratory findings were obtained using standard questionnaires/ protocols. Body composition was measured using bioelectric impedance analyser and bone health by dual-energy X-ray absorptiometry (DXA).
results37 were growth hormone (GH) naïve and 33 had received GH for at least a year. 34.3% had attained menarche before DXA assessment and 54.3% were on estrogen (E2) replacement. Mean age at GH initiation was 9.5 ± 2.6 years. E2 replacement was initiated at a mean age of 13.5 ± 1.3 years. Girls treated with GH had better height outcomes and height & SMR-adjusted lean mass, total body less head areal bone mineral density (TBLH aBMD), lumbar spine aBMD and lumbar spine bone mineral apparent density Z-scores. Multiple linear regression showed cumulative GH dose, FSH and height to be significant predictors of TBLH aBMD Z-score. Cumulative GH and E2 doses and lean mass percentage Z-score significantly predicted lumbar spine aBMD Z-scores.
conclusionBone health is often overlooked in TS due to other clinical issues. Timely and adequate intervention with estrogen and GH is likely to have better bone mineral density outcomes by improving bone accrual and muscle mass in individuals with TS.
Indexed as
Identifiers
41460421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.